Alumis Inc.
ALMS
Rankning i aktier
#9783
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Aktiekurs
$6.78
Senast synkroniserad: 2026-10-21
Marknadsvärde
$877.57M
Förändring (1 dag)
1.19%
Förändring (1 år)
198.68%
Land
US
Handel Alumis Inc. (ALMS)
Kategori
Healthcare
Aktiekurshistorik för Alumis Inc. (ALMS)
Högsta slutkurs: $2.34 den 2025-05-01
Lägsta slutkurs: $21.58 den 2023-05-01
Lägsta slutkurs: $21.58 den 2023-05-01
Aktiekurshistorik för Alumis Inc. från 2023 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2025 | -35.06% |
| 2024 | -49.49% |
| 2023 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.70 | 7.84% |
CH
|
